Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.68 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | CDK2 | P24941 | 3/20 | 0.52 |
| ▸ | CDK4 | P11802 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779291 | 0.95 | KCNH2 (0.68) | KCNH2EGFRTGFBR1GSK3BCDK2 | |
| SCHEMBL5780635 | 0.92 | KCNH2 (0.57) | KCNH2EGFRGSK3BCDK2CDK4 | |
| SCHEMBL5781152 | 0.88 | CDK4 (0.59) | KCNH2EGFRTGFBR1GSK3BCDK2 | |
| SCHEMBL6624925 | 0.87 | GSK3B (0.54) | KCNH2GSK3BCDK2CDK4MAPK14 | |
| SCHEMBL5782345 | 0.86 | PIK3CG (0.70) | KCNH2EGFRTGFBR1GSK3BCDK2 | |
| SCHEMBL5779236 | 0.85 | KCNH2 (0.59) | KCNH2EGFRTGFBR1GSK3BCDK2 | |
| SCHEMBL6609023 | 0.83 | EGFR (0.55) | KCNH2EGFRTGFBR1GSK3BCDK2 | |
| SCHEMBL5781477 | 0.83 | EGFR (0.57) | KCNH2EGFRTGFBR1GSK3BCDK2 | |
| SCHEMBL5780601 | 0.83 | EGFR (0.55) | KCNH2EGFRTGFBR1GSK3BCDK2 | |
| SCHEMBL5781915 | 0.83 | EGFR (0.55) | KCNH2EGFRTGFBR1GSK3BCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105517-B2 | Thiazolyl substituted aminopyrimidines as plant protection agents | SYNGENTA CROP PROTECTION, INC. (US) | 2006-09-12 | — | — | US | claimed |
| EP-1434776-B1 | THIAZOLYL SUBSTITUTED AMINOPYRIMIDINES AS PLANT PROTECTION AGENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2006-06-28 | — | — | EP | claimed |
| US-20050038059-A1 | Thiazolyl substituted aminopyrimidines as plant protection agents | SYNGENTA CROP PROTECTION, INC. | 2005-02-17 | — | — | US | claimed |
| EP-1434776-A1 | THIAZOLYL SUBSTITUTED AMINOPYRIMIDINES AS PLANT PROTECTION AGENTS | Syngenta Participations AG (CH) | 2004-07-07 | — | — | EP | claimed |
| WO-2003029249-A1 | THIAZOLYL SUBSTITUTED AMINOPYRIMIDINES AS PLANT PROTECTION AGENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2003-04-10 | — | — | WO | claimed |
| US-7105517-B2 | Thiazolyl substituted aminopyrimidines as plant protection agents | SYNGENTA CROP PROTECTION, INC. (US) | 2006-09-12 | — | — | US | disclosed |
| EP-1434776-B1 | THIAZOLYL SUBSTITUTED AMINOPYRIMIDINES AS PLANT PROTECTION AGENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2006-06-28 | — | — | EP | disclosed |
| US-20050038059-A1 | Thiazolyl substituted aminopyrimidines as plant protection agents | SYNGENTA CROP PROTECTION, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038059-A1 | Thiazolyl substituted aminopyrimidines as plant protection agents | RARS2, CYP4X1, QDPR | KCNH2 239/4885EGFR 2883/4885TGFBR1 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.